Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial

CONCLUSIONS: First line metronomic chemotherapy for HER2 negative ABC had similar clinical activity and quite better tolerability than standard schedule and could be considered a further treatment option when chemotherapy is indicated.PMID:38615483 | DOI:10.1016/j.breast.2024.103725

Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Laura Orlando Evaristo Maiello Michele Orditura Anna Diana Giuliano Antoniol Maria Grazia Morritti Michele Aieta Mariangela Ciccarese Salvatore Pisconti Roberto Bordonaro Antonio Russo Antonio Febbraro Paola Schiavone Annamaria Quaranta Chiara Caliolo Dar Source Type: research